3[4]Kantor P F ,Lucien A, Kozak R ,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J].Circ Res , 2000 , 86(5) : 580～588.
4[5]Recommendations of the Task Force of the France Society of Cardiology. Management of stabl eangina-pectoris[J].Eur Heart J,1997,18(3):294～413.
5[7]WILLIAMS F M , TANDA K , KUS M , et al . Trimetazidine inhibits meutrophil accumulation after myocardial ischemia and reperfusion in rabbits[J].J Cardiovasc Pharmacol , 1993 , 22(6) : 823～833.
8[2]Vila V,Martinez-Sale V,Reganon E,et al.Effects of unfractionatedand low molecular weight heparins on plasma level of hemostatic factorsin patients with acute coronary syndromes.Hacmatologica,2001,86:729-734.
9[3]Goodman SG,Cohen M,Bigonzi F,et al.Randomized trial of low molecular weight heparin(enoxaparin)versus unfractionated heparin for unstable coronary artery disease:one year results of the ESSENCE Study.Ettlcacy and safety of Subcutaneous Enoxapacinin Non-O-Wave Coronary Events.J Am Coll Cardiol,2000,36:693-698.
10[4]Antman EM,Cohen M,Radley D,et al.For the TIMI II B and ESSENCE Investigatom.Assessment 0f the treatment effect of enoxaparin for unstable angina non-Q-wave myocardial infarction.TIMI II B ESSENCE meta-analysis.Circulafion,1999,100:1602-1608.
